ARTIVION, INC. - 8-K Filing
Artivion completed the acquisition of Endospan Ltd., an Israeli company specializing in aortic instability treatments, on May 18, 2026. The base purchase price was $175 million, paid entirely in cash with adjustments resulting in a net payment of approximately $131.3 million by Artivion's subsidiary CryoLife Asia Pacific Pte. Ltd. An additional up to $200 million in contingent consideration is possible based on the future performance of Endospan’s Nexus product. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $AORT